تداخلات توبرامايسين

Because the nephrotoxic effects may be additive, the concomitant or sequential use of Pentamidine Isethionate and other nephrotoxic drugs such as aminoglycosides, amphotericin B, cisplatin, foscarnet, or vancomycin should be closely monitored and avoided, if possible. (نشرة بنتاميدين، التداخلات الدوائية)

THE CONCURRENT OR SEQUENTIAL USE OF OTHER NEUROTOXIC AND/OR NEPHROTOXIC DRUGS WITH POLYMYXIN B SULFATE, PARTICULARLY BACITRACIN, STREPTOMYCIN, NEOMYCIN, KANAMYCIN, GENTAMICIN, TOBRAMYCIN, AMIKACIN, CEPHALORIDINE, PAROMOMYCIN, VIOMYCIN, AND COLISTIN SHOULD BE AVOIDED. (نشرة بوليميكسين ب، تحذير مؤطر)

Drug Interactions Drugs with Ototoxic Potential (see WARNINGS ) Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. (نشرة بوميتانيد، التداخلات الدوائية)

Avoid concomitant use of torsemide and aminoglycoside antibiotics, if possible. (نشرة توراسيميد، التداخلات الدوائية)

Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, and viomycin, should be avoided (see PRECAUTIONS, Drug Interactions section). (نشرة جنتاميسين، تحذير مؤطر)

TOBI Podhaler should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. (نشرة توبرامايسين، التداخلات الدوائية)

In vitro mixing of penicillins and aminoglycosides should be avoided during concomitant therapy and the drugs should be administered separately. (نشرة ديكلوكساسيلين، التداخلات الدوائية)

TOBI Podhaler should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. (نشرة توبرامايسين، التداخلات الدوائية)

Because of foscarnet's tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, acyclovir, methotrexate, tacrolimus and intravenous pentamidine (see above) unless the potential benefits outweigh the risks to the patient. (نشرة فوسكارنت، التداخلات الدوائية)

Aminoglycosides : Avoid concomitant use with aminoglycosides. (نشرة كاربوبلاتين، التداخلات الدوائية)

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (نشرة نيومايسين، تحذير مؤطر)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (نشرة أتراكوريوم، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (نشرة أديفوفير، التحذيرات والاحتياطات)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (نشرة إلفيتيغرافير وكوبيسيستات وإمتريسيتابين وتينوفوفير، التداخلات الدوائية)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (نشرة إمتريسيتابين وتينوفوفير، التداخلات الدوائية)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.5) ] . (نشرة إمتريسيتابين وريلبيفيرين وتينوفوفير، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Aminoglycosides or other agents that interfere with neuromuscular transmission may potentiate the effect of XEOMIN; co-administer only with caution and close observation ( 7 ) (نشرة إنكوبوتولينوم توكسين A، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Patients receiving concomitant treatment of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of BOTOX may be potentiated ( 7.1 , 7.4 ) (نشرة أونابوتولينوم توكسين A، التداخلات الدوائية)

Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (نشرة إيفافيرينز ولاميفودين وتينوفوفير، التداخلات الدوائية)

Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (نشرة بيبراسيلين وتازوباكتام، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (نشرة تاكروليموس، التحذيرات والاحتياطات)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (نشرة توكسين البوتولينوم من النمط A، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.2) ]. (نشرة تينوفوفير، التداخلات الدوائية)

• Aminoglycosides: May lower serum calcium for prolonged periods ( 7.1 ) (نشرة حمض الزوليدرونيك، التداخلات الدوائية)

Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as Rocuronium Bromide Injection include certain antibiotics (e.g., aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). (نشرة روكورونيوم، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

The safety of cidofovir injection has not been evaluated in patients receiving other known potentially nephrotoxic agents, such as intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents (see DOSAGE AND ADMINISTRATION ). (نشرة سيدوفوفير، التحذيرات)

Caution should be exercised when using agents (e.g., aminoglycosides and amphotericin B) that are known to have a deleterious effect on renal function. (نشرة سيروليموس، التحذيرات والاحتياطات)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics. (نشرة سيفبروزيل، التداخلات الدوائية)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (نشرة سيفتازيديم، التداخلات الدوائية)

Vancomycin, Amsacrine, Aminoglycosides, and Fluconazole Vancomycin, amsacrine, aminoglycosides, and fluconazole are physically incompatible with ceftriaxone in admixtures [see Dosage and Administration (2.3) ]. (نشرة سيفترياكسون، التداخلات الدوائية)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (نشرة سيفوتاكسيم، التداخلات الدوائية)

If CEFOTAN® and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated. (نشرة سيفوتيتان، الاحتياطات)

Aminoglycosides: Increased potential of nephrotoxicity. (نشرة سيفوكسيتين، التداخلات الدوائية)

Aminoglycosides: Increased potential of nephrotoxicity and ototoxicity. (نشرة سيفيبيم، التداخلات الدوائية)

…ciprofloxacin melphalan amphotericin B azapropazon cimetidine tacrolimus fibric acid derivatives (e.g., bezafibrate, fenofibrate) gentamicin ketoconazole colchicine ranitidine methotrexate tobramycin diclofenac trimethoprim with sulfamethoxazole naproxen vancomycin sulindac During the concomitant use of a drug that may exhibit additive or synergistic renal impairment… (نشرة سيكلوسبورين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

The risk is higher in older patients, patients who are receiving higher doses, who have an underlying hearing loss, who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside or who have underlying renal impairment. (نشرة فانكومايسين، التحذيرات والاحتياطات)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (نشرة ميكوفينولات، التداخلات الدوائية)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

UNASYN and aminoglycosides should not be reconstituted together due to the in vitro inactivation of aminoglycosides by the ampicillin component of UNASYN. (نشرة أمبيسيلين وسولباكتام، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

Before therapy with ZEMDRI is instituted, careful inquiry about previous hypersensitivity reactions to other aminoglycosides should be made. (نشرة بلازوميسين، التحذيرات والاحتياطات)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all. (نشرة بيريدوستيغمين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

The following antibiotics have been associated with various degrees of paralysis: aminoglycosides (such as neomycin, streptomycin, kanamycin, gentamicin, and dihydrostreptomycin); tetracyclines; bacitracin; polymyxin B; colistin; and sodium colistimethate. (نشرة فيكورونيوم، الاحتياطات)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

Drug Interactions Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction. (نشرة كوليستيميثات، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

…assess the need for additional doses of Cisatracurium Besylate Injection, and to determine whether adjustments need to be made to the dose with subsequent administration. † Examples: aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, sodium colistimethate Drug or Drug Class Clinical Implications * Succinylcholine The use of… (نشرة سيساتراكوريوم، التداخلات الدوائية)